Brookline Capital Markets Weighs in on CADL Q3 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Stock analysts at Brookline Capital Markets dropped their Q3 2026 EPS estimates for shares of Candel Therapeutics in a note issued to investors on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.33) for the quarter, down from their prior estimate of ($0.26). The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.03) per share. Brookline Capital Markets also issued estimates for Candel Therapeutics’ Q4 2026 earnings at ($0.32) EPS.

Other equities analysts have also issued reports about the company. UBS Group restated a “buy” rating on shares of Candel Therapeutics in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Candel Therapeutics in a research note on Thursday, August 13th. Stifel Nicolaus began coverage on Candel Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $22.00 price objective on the stock. Wall Street Zen downgraded Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Friday, July 17th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.29.

Candel Therapeutics Trading Up 3.8%

Candel Therapeutics stock opened at $12.16 on Monday. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09. The company has a market capitalization of $930.48 million, a price-to-earnings ratio of -8.62 and a beta of -0.51. Candel Therapeutics has a one year low of $4.35 and a one year high of $12.49. The company’s fifty day moving average price is $9.75 and its two-hundred day moving average price is $7.45.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.28).

Institutional Investors Weigh In On Candel Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE bought a new position in shares of Candel Therapeutics in the second quarter worth about $2,873,000. Legal & General Group Plc bought a new stake in shares of Candel Therapeutics in the second quarter valued at about $63,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Candel Therapeutics during the 2nd quarter worth approximately $175,000. BlackRock Inc. acquired a new position in shares of Candel Therapeutics in the second quarter valued at $51,181,000. Finally, Deutsche Bank AG bought a new position in Candel Therapeutics in the second quarter worth $648,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.02, for a total transaction of $70,140.00. Following the completion of the transaction, the chief technology officer owned 83,865 shares of the company’s stock, valued at $840,327.30. The trade was a 7.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Francesca Barone sold 23,447 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $10.06, for a total transaction of $235,876.82. Following the sale, the insider owned 77,362 shares of the company’s stock, valued at $778,261.72. This trade represents a 23.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 14.30% of the company’s stock.

Candel Therapeutics News Roundup

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target for Candel Therapeutics to $12.00, providing a more favorable valuation signal. However, the new target is roughly in line with the stock’s recent trading level, suggesting limited implied upside from that estimate. Candel Therapeutics Price Target Raised to $12.00
• Neutral Sentiment: An analyst forecast for Candel’s fiscal 2028 earnings was reported, giving investors a longer-term reference point, although the article does not indicate a material change to the company’s near-term valuation. What is HC Wainwright’s Forecast for CADL FY2028 Earnings?
• Negative Sentiment: HC Wainwright adopted a pessimistic outlook for Candel’s third-quarter earnings, adding pressure to expectations for the company’s next results. HC Wainwright Has Pessimistic Outlook of CADL Q3 Earnings
• Negative Sentiment: An analyst reduced Candel’s third-quarter EPS estimate, signaling expectations for a wider loss or weaker-than-previously-forecast results. Q3 EPS Estimate for Candel Therapeutics Decreased by Analyst
• Negative Sentiment: Candel shares previously fell after disappointing quarterly earnings. The company reported a quarterly loss of $0.52 per share, worse than the $0.24 analyst consensus, highlighting continued earnings risk. Candel Therapeutics Stock Price Down 4.6% on Disappointing Earnings
• Negative Sentiment: Wall Street Zen downgraded Candel Therapeutics to Sell, reinforcing the cautious view surrounding the company’s profitability and earnings outlook. Wall Street Zen Downgrades Candel Therapeutics to Sell

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.